Cargando…

Efficacy and Safety of Pomegranate Medicinal Products for Cancer

Preclinical in vitro and in vivo studies demonstrate potent effects of pomegranate preparations in cancer cell lines and animal models with chemically induced cancers. We have carried out one systematic review of the effectiveness of pomegranate products in the treatment of cancer and another on the...

Descripción completa

Detalles Bibliográficos
Autores principales: Vlachojannis, Christian, Zimmermann, Benno F., Chrubasik-Hausmann, Sigrun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359844/
https://www.ncbi.nlm.nih.gov/pubmed/25815026
http://dx.doi.org/10.1155/2015/258598
_version_ 1782361479805140992
author Vlachojannis, Christian
Zimmermann, Benno F.
Chrubasik-Hausmann, Sigrun
author_facet Vlachojannis, Christian
Zimmermann, Benno F.
Chrubasik-Hausmann, Sigrun
author_sort Vlachojannis, Christian
collection PubMed
description Preclinical in vitro and in vivo studies demonstrate potent effects of pomegranate preparations in cancer cell lines and animal models with chemically induced cancers. We have carried out one systematic review of the effectiveness of pomegranate products in the treatment of cancer and another on their safety. The PubMed search provided 162 references for pomegranate and cancer and 122 references for pomegranate and safety/toxicity. We identified 4 clinical studies investigating 3 pomegranate products, of which one was inappropriate because of the low polyphenol content. The evidence of clinical effectiveness was poor because the quality of the studies was poor. Although there is no concern over safety with the doses used in the clinical studies, pomegranate preparations may be harmful by inducing synthetic drug metabolism through activation of liver enzymes. We have analysed various pomegranate products for their content of anthocyanins, punicalagin, and ellagic acid in order to compare them with the benchmark doses from published data. If the amount of coactive constituents is not declared, patients risk not benefiting from the putative pomegranate effects. Moreover, pomegranate end products are affected by many determinants. Their declaration should be incorporated into the regulatory guidance and controlled before pomegranate products enter the market.
format Online
Article
Text
id pubmed-4359844
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-43598442015-03-26 Efficacy and Safety of Pomegranate Medicinal Products for Cancer Vlachojannis, Christian Zimmermann, Benno F. Chrubasik-Hausmann, Sigrun Evid Based Complement Alternat Med Review Article Preclinical in vitro and in vivo studies demonstrate potent effects of pomegranate preparations in cancer cell lines and animal models with chemically induced cancers. We have carried out one systematic review of the effectiveness of pomegranate products in the treatment of cancer and another on their safety. The PubMed search provided 162 references for pomegranate and cancer and 122 references for pomegranate and safety/toxicity. We identified 4 clinical studies investigating 3 pomegranate products, of which one was inappropriate because of the low polyphenol content. The evidence of clinical effectiveness was poor because the quality of the studies was poor. Although there is no concern over safety with the doses used in the clinical studies, pomegranate preparations may be harmful by inducing synthetic drug metabolism through activation of liver enzymes. We have analysed various pomegranate products for their content of anthocyanins, punicalagin, and ellagic acid in order to compare them with the benchmark doses from published data. If the amount of coactive constituents is not declared, patients risk not benefiting from the putative pomegranate effects. Moreover, pomegranate end products are affected by many determinants. Their declaration should be incorporated into the regulatory guidance and controlled before pomegranate products enter the market. Hindawi Publishing Corporation 2015 2015-03-01 /pmc/articles/PMC4359844/ /pubmed/25815026 http://dx.doi.org/10.1155/2015/258598 Text en Copyright © 2015 Christian Vlachojannis et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Vlachojannis, Christian
Zimmermann, Benno F.
Chrubasik-Hausmann, Sigrun
Efficacy and Safety of Pomegranate Medicinal Products for Cancer
title Efficacy and Safety of Pomegranate Medicinal Products for Cancer
title_full Efficacy and Safety of Pomegranate Medicinal Products for Cancer
title_fullStr Efficacy and Safety of Pomegranate Medicinal Products for Cancer
title_full_unstemmed Efficacy and Safety of Pomegranate Medicinal Products for Cancer
title_short Efficacy and Safety of Pomegranate Medicinal Products for Cancer
title_sort efficacy and safety of pomegranate medicinal products for cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359844/
https://www.ncbi.nlm.nih.gov/pubmed/25815026
http://dx.doi.org/10.1155/2015/258598
work_keys_str_mv AT vlachojannischristian efficacyandsafetyofpomegranatemedicinalproductsforcancer
AT zimmermannbennof efficacyandsafetyofpomegranatemedicinalproductsforcancer
AT chrubasikhausmannsigrun efficacyandsafetyofpomegranatemedicinalproductsforcancer